关键词:

肺癌, 化疗, 头孢他啶, 肺部感染, 防治效果

Abstract:

Objective　To observe the application of ceftazidime injection in adjuvant chemotherapy for lung cancer and its prevention and control effect of lung infection. Methods　It was a randomized controlled trial. A total of 98 patients with lung cancer admitted to The First People's Hospital of Shangqiu City from January 2020 to August 2021 were included as the research objects. They were divided into an observation group and a control group by the lottery method, with 49 cases in each group. In the observation group, there were 30 males and 19 females, aged (55.33±5.16) years; in the control group, there were 33 males and 16 females, aged (55.25±5.32) years. Both groups received chemotherapy, and the observation group received ceftazidime injection as adjuvant chemotherapy. The changes of serum inflammatory factors and blood gas indexes before and after treatment, the changes of Clinical Pulmonary Infection Score (CPIS) after 1, 3, and 7 days of treatment, and the incidence of pulmonary infection were compared between the two groups. A 1-year follow-up was conducted after treatment to compare the long-term survival of the two groups. χ² test and independent sample t test were used. Results　Before treatment, there were no statistically significant differences in the serum inflammatory factors and blood gas indexes between the two groups (all P>0.05). After treatment, the levels of C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), and other inflammatory factors were increased in both groups, but the above indexes in the observation group were lower than those in the control group (all P<0.05); the partial pressure of arterial oxygen (PaO₂), oxygen saturation (SaO₂), oxygenation index (PaO₂/FiO₂), and other blood gas indexes were decreased in both groups, but the above indexes in the observation group were higher than those in the control group (all P<0.05). The CPIS of the observation group after 1, 3, and 7 days of treatment were lower than those of the control group [(6.97±1.21) points vs. (7.62±1.35) points, (5.82±0.74) points vs. (6.33±0.65) points, (4.52±0.45) points vs. (5.03±0.17) points], and the incidences of pulmonary infection were lower than those of the control group [10.20% (5/49) vs. 20.41% (10/49), 4.08% (2/49) vs. 14.29% (7/49), 0.20% (1/49) vs. 10.20% (5/49)], with statistically significant differences (all P<0.05). During the follow-up period, the scores of all dimension of Functional Assessment of Cancer Therapy - Lung cancer (FACT-L) in the observation group were higher than those in the control group (all P<0.05). Conclusion　The use of ceftazidime injection as an adjuvant therapy during chemotherapy for lung cancer patients can promote the recovery of inflammatory response and arterial blood gas indicators, which has positive significance in reducing the risk of lung infection and improving the long-term quality of life.

Key words:

Lung cancer, Chemotherapy, Ceftazidime, Pulmonary infection, Prevention and control effect